Abstract
Certain bacteria selectively attack tumor tissues and trigger tumor shrinkage by producing toxins and modulating the local immune system, but their clinical utility is limited because of the dangers posed by systemic infection. Genetic engineering can be used to minimize the risks associated with tumor-targeting pathogens, as well as to increase their efficiency in killing tumor cells. Advances in genetic circuit design have led to the development of bacterial strains with enhanced tumor-targeting capacities and the ability to secrete therapeutics, cytotoxic proteins and prodrug-cleaving enzymes, which allows their safe and effective use for cancer treatment. The present review details the recent advances in the design and application of these modified bacterial strains.
Keywords: Synthetic biology, cancer therapy, live vaccines, prodrug cleavage, Salmonella, Clostridium, Bifidobacterium.
Current Pharmaceutical Design
Title:Biosystems Engineering of Prokaryotes with Tumor-Killing Capacities
Volume: 22 Issue: 11
Author(s): Ebuzer Kalyoncu, Tolga T. Olmez, Alper D. Ozkan and Omer F. Sarioglu
Affiliation:
Keywords: Synthetic biology, cancer therapy, live vaccines, prodrug cleavage, Salmonella, Clostridium, Bifidobacterium.
Abstract: Certain bacteria selectively attack tumor tissues and trigger tumor shrinkage by producing toxins and modulating the local immune system, but their clinical utility is limited because of the dangers posed by systemic infection. Genetic engineering can be used to minimize the risks associated with tumor-targeting pathogens, as well as to increase their efficiency in killing tumor cells. Advances in genetic circuit design have led to the development of bacterial strains with enhanced tumor-targeting capacities and the ability to secrete therapeutics, cytotoxic proteins and prodrug-cleaving enzymes, which allows their safe and effective use for cancer treatment. The present review details the recent advances in the design and application of these modified bacterial strains.
Export Options
About this article
Cite this article as:
Kalyoncu Ebuzer, Olmez T. Tolga, Ozkan D. Alper and Sarioglu F. Omer, Biosystems Engineering of Prokaryotes with Tumor-Killing Capacities, Current Pharmaceutical Design 2016; 22 (11) . https://dx.doi.org/10.2174/1381612822666151210123752
DOI https://dx.doi.org/10.2174/1381612822666151210123752 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Strategies for Targeting the Multidrug Resistance-1 (MDR1)/P-gp Transporter in Human Malignancies
Current Cancer Drug Targets Aminolevulinic Acid Derivatives and Liposome Delivery as Strategies for Improving 5-Aminolevulinic Acid- Mediated Photodynamic Therapy
Current Medicinal Chemistry The J-shaped Association Between Alcohol Consumption and Breast Cancer: A Case-Control Study
Current Nutrition & Food Science Current and Next Generation Topical Anti-Skin Cancer Therapeutics
Drug Delivery Letters LRIGs: A Prognostically Significant Family with Emerging Therapeutic Competence against Cancers
Current Cancer Drug Targets A2B Receptor Ligands: Past, Present and Future Trends
Current Topics in Medicinal Chemistry HtrA Serine Proteases as Potential Therapeutic Targets in Cancer
Current Cancer Drug Targets microRNA Biogenesis Pathway as a Therapeutic Target for Human Disease and Cancer
Current Pharmaceutical Design Involvement of Cysteine Proteases in Cancer
Current Medicinal Chemistry Current Concepts on the Management of Chordoma
Current Drug Therapy Aqueous Extracts of Selected Potentilla Species Modulate Biological Activity of Human Normal Colon Cells
Current Drug Targets Pharmacogenetics Strategies: From Candidate Genes to Whole-Genome Association Analysis. Exploratory or Confirmatory Studies?
Current Pharmacogenomics and Personalized Medicine A Neuroinformatics Study Describing Molecular Interaction of Cisplatin with Acetylcholinesterase: A Plausible Cause for Anticancer Drug Induced Neurotoxicity
CNS & Neurological Disorders - Drug Targets Application of Genetic Polymorphisms in DNA Repair in the Prediction of Cancer Susceptibility and Clinical Outcome
Current Pharmacogenomics <i>Uncaria tomentosa</i> (Willd. ex Schult.): Focus on Nutraceutical Aspects
Current Bioactive Compounds Law-Medicine Interfacing: Patenting of Human Genes and Mutations
Recent Patents on DNA & Gene Sequences Oxytocin - A Multifunctional Analgesic for Chronic Deep Tissue Pain
Current Pharmaceutical Design Minimally Invasive Approach to Endometrial Cancer: Robotics and Laparoscopy
Current Women`s Health Reviews Immunotherapy in Bladder Cancer
Current Molecular Pharmacology Furan-induced Oxidative Stress and DNA Damage in Diabetic and Nondiabetic Rats’ Blood and Protective Effect of Lycopene
Current Nutrition & Food Science